CO6241112A2 - Sales novedosas de piperazina como antagonistas d3/d2 - Google Patents

Sales novedosas de piperazina como antagonistas d3/d2

Info

Publication number
CO6241112A2
CO6241112A2 CO09139912A CO09139912A CO6241112A2 CO 6241112 A2 CO6241112 A2 CO 6241112A2 CO 09139912 A CO09139912 A CO 09139912A CO 09139912 A CO09139912 A CO 09139912A CO 6241112 A2 CO6241112 A2 CO 6241112A2
Authority
CO
Colombia
Prior art keywords
dimethylcarbamoyl
cyclohexylamine
piperazin
dichlorophenyl
trans
Prior art date
Application number
CO09139912A
Other languages
English (en)
Inventor
Csongor Eva Againe
Laszlo Czibula
Istvan Greiner
Gyorgy Domany
Ferenc Sebok
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of CO6241112A2 publication Critical patent/CO6241112A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)

Abstract

1.- Monoclorhidrato de trans 4- {2-[4-(2,3-diclorofenil)-piperazin-1-il]-etil}-N,N-dimetilcarbamoil-ciclohexilamina y/o hidratos y/o solvatos del mismo. 2.- Monoclorhidrato de trans 4- {2-[4-(2,3-diclorofenil)-piperazin-1-il]-etil}-N,N-dimetilcarbamoil-ciclohexilamina y/o hidratos y/o solvatos del mismo. 3.- Monobromhidrato de trans 4-{2-[4-(2,3-diclorofenil)-piperazin-1-il]-etil}-N,N-dimetilcarbamoil-ciclohexilamina y/o hidratos y/o solvatos del mismo. 4.- Maleato de trans 4-{2-[4-(2,3-diclorofenil)-piperazin-1-iI]-etil}-N,N-dimetilcarbamoil-ciclohexilamina y/o hidratos y/o solvatos del mismo. 5.- Metanosulfonato de trans 4-{2-[4-(2,3-diclorofenil)-piperazin-1-il]-etil}-N,N-dimetilcarbamoil-ciclohexilamina y/o hidratos y/o solvatos del mismo. 6.- Procedimiento para la preparación de los compuestos de las reivindicaciones 1-5, caracterizado porque la base trans 4-{2-[4-(2,3-diclorofenil)-piperazin-1-il]-etil}-N,N-dimetilcarbamoil-ciclohexilamina se disuelve o suspende en un disolvente o mezcla de disolventes adecuados y, a continuación, se adiciona un ácido, o una sal del mismo preparada con una base más débil que la trans 4-{2-[4-(2,3-diclorofenil)-piperazin-1-il]-etil}-N,N-dimetilcarbamoil-ciclohexilamina, o una disolución de la misma, y, opcionalmente, la mezcla de reacción se concentra y/o enfría y, a continuación, el producto obtenido se aísla mediante filtración. 7.- Una composición farmacéutica que comprende un compuesto según una cualquiera de las reivindicaciones 1-5 y uno o más ingredientes farmacéuticamente aceptables. 8.- Uso de un compuesto según una cualquiera de las reivindicaciones 1-5 y/o hidratos y/o solvatos del mismo para la fabricación de un medicamento para el tratamiento y/o prevención de trastornos que requieren la modulación de un receptor de dopamina.
CO09139912A 2007-05-11 2009-12-07 Sales novedosas de piperazina como antagonistas d3/d2 CO6241112A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0700339A HU230748B1 (hu) 2007-05-11 2007-05-11 Új piperazin só és előállítási eljárása

Publications (1)

Publication Number Publication Date
CO6241112A2 true CO6241112A2 (es) 2011-01-20

Family

ID=89987512

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09139912A CO6241112A2 (es) 2007-05-11 2009-12-07 Sales novedosas de piperazina como antagonistas d3/d2

Country Status (35)

Country Link
US (1) US7943621B2 (es)
EP (1) EP2155696B1 (es)
JP (1) JP2010526861A (es)
KR (2) KR20100018493A (es)
CN (1) CN101679315B (es)
AP (1) AP2009005012A0 (es)
AU (1) AU2008249772B2 (es)
BR (1) BRPI0811199A2 (es)
CA (1) CA2684404C (es)
CO (1) CO6241112A2 (es)
CY (1) CY1119076T1 (es)
DK (1) DK2155696T3 (es)
EA (1) EA017270B1 (es)
EC (1) ECSP099772A (es)
ES (1) ES2628025T3 (es)
GE (1) GEP20125522B (es)
HK (1) HK1140473A1 (es)
HR (1) HRP20170918T1 (es)
HU (2) HU230748B1 (es)
IL (1) IL201533A0 (es)
LT (1) LT2155696T (es)
MA (1) MA31434B1 (es)
MX (1) MX2009012182A (es)
MY (1) MY148078A (es)
NI (1) NI200900203A (es)
NZ (1) NZ580642A (es)
PL (1) PL2155696T3 (es)
PT (1) PT2155696T (es)
RS (1) RS56036B1 (es)
SI (1) SI2155696T1 (es)
TN (1) TN2009000458A1 (es)
TW (1) TWI424846B (es)
UA (1) UA102225C2 (es)
WO (1) WO2008139235A2 (es)
ZA (1) ZA200907511B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017732B1 (ru) * 2007-05-11 2013-02-28 Рихтер Гедеон Нирт. Сольватная и кристаллическая формы гидрохлорида транс-1{4-[2-[4-(2,3-дихлорфенил)пиперазин-1-ил]этил]циклогексил}-3,3-диметилмочевины, способы их получения и их применение в фармацевтических композициях и способах лечения состояний, для которых необходима модуляция дофаминовых рецепторов
HUP0700353A2 (en) 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
HUP0700369A2 (en) 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
EA018064B1 (ru) * 2007-08-03 2013-05-30 Рихтер Гедеон Нирт. Способ лечения депрессии
US7875610B2 (en) * 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
EA023972B1 (ru) * 2008-02-21 2016-08-31 Рихтер Гедеон Нирт. Стабильный твёрдый препарат карипразина для перорального введения и способ его получения
MY156288A (en) 2008-07-16 2016-01-29 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands.
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
HU231227B1 (hu) 2012-11-29 2022-03-28 Richter Gedeon Nyrt. Transz-4-{2-[4-(2,3-diklórfenil)-piperazin-1-il]-etil}N,N-dimetilkarbamoil-ciklohexilamin skizofrénia negatív tüneteinek kezelésére
CN105218484B (zh) * 2015-09-14 2018-02-23 安徽省逸欣铭医药科技有限公司 酒石酸卡利拉嗪及其制备方法和医药用途
CN106543105B (zh) * 2015-09-22 2019-10-11 江苏恩华药业股份有限公司 一种盐酸卡利拉嗪晶型ⅳ及其制备方法
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
WO2018229794A1 (en) 2017-06-13 2018-12-20 Cipla Limited Amorphous form of cariprazine
WO2019016828A1 (en) * 2017-07-15 2019-01-24 Msn Laboratories Private Limited, R&D Center NOVEL PROCESSES FOR THE PREPARATION OF TRANS-N- {4- [2- [4- (2,3-DICHLOROPHENYL) PIPERAZIN-1-YL] ETHYL] CYCLOHEXYL} -N ', N'-DIMETHYLUMED HYDROCHLORIDE AND POLYMORPHS THIS ONE
WO2020056929A1 (zh) * 2018-09-21 2020-03-26 上海诚妙医药科技有限公司 卡利拉嗪盐酸盐的新晶型及其制备方法及其用途
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
JP2023540056A (ja) 2020-08-26 2023-09-21 上海雲晟研新生物科技有限公司 カリプラジン薬用塩及びその結晶形、製造方法及び応用
WO2023077094A1 (en) * 2021-10-28 2023-05-04 Abbvie Inc. Treatment of major depressive disorder
WO2024072930A1 (en) * 2022-09-30 2024-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
HU227534B1 (en) * 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
HUP0500170A3 (en) * 2005-02-03 2007-11-28 Richter Gedeon Nyrt Piperazine derivatives, process for producing them and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
MX2009012182A (es) 2009-12-09
TW201002323A (en) 2010-01-16
HU0700339D0 (en) 2007-07-30
WO2008139235A8 (en) 2009-12-03
DK2155696T3 (en) 2017-07-10
CA2684404C (en) 2013-02-05
CA2684404A1 (en) 2008-11-20
HU230748B1 (hu) 2018-02-28
ES2628025T3 (es) 2017-08-01
US20090023750A1 (en) 2009-01-22
PT2155696T (pt) 2017-06-02
BRPI0811199A2 (pt) 2014-10-29
HRP20170918T1 (hr) 2017-09-22
CY1119076T1 (el) 2018-01-10
AU2008249772B2 (en) 2013-09-05
MY148078A (en) 2013-02-28
JP2010526861A (ja) 2010-08-05
UA102225C2 (ru) 2013-06-25
TWI424846B (zh) 2014-02-01
RS56036B1 (sr) 2017-09-29
KR20100018493A (ko) 2010-02-17
GEP20125522B (en) 2012-05-25
AP2009005012A0 (en) 2009-10-31
US7943621B2 (en) 2011-05-17
SI2155696T1 (sl) 2017-08-31
KR101668973B1 (ko) 2016-10-24
HUP0700339A2 (en) 2009-04-28
MA31434B1 (fr) 2010-06-01
CN101679315A (zh) 2010-03-24
AU2008249772A1 (en) 2008-11-20
LT2155696T (lt) 2017-06-12
EP2155696B1 (en) 2017-03-22
NI200900203A (es) 2010-03-11
EA017270B1 (ru) 2012-11-30
WO2008139235A3 (en) 2009-03-12
HK1140473A1 (en) 2010-10-15
WO2008139235A2 (en) 2008-11-20
HUP0700339A3 (en) 2010-01-28
KR20150090264A (ko) 2015-08-05
HUE034796T2 (en) 2018-03-28
ECSP099772A (es) 2009-12-28
PL2155696T3 (pl) 2017-10-31
TN2009000458A1 (en) 2011-03-31
CN101679315B (zh) 2013-06-12
EA200971046A1 (ru) 2010-04-30
EP2155696A2 (en) 2010-02-24
NZ580642A (en) 2012-02-24
ZA200907511B (en) 2010-07-28
IL201533A0 (en) 2010-05-31

Similar Documents

Publication Publication Date Title
CO6241112A2 (es) Sales novedosas de piperazina como antagonistas d3/d2
NI202000078A (es) Compuestos heteroaril tetracíclicos
NI201900039A (es) Derivados de 6, 7, 8, 9-tetrahidro-3h-pirazolo[4, 3-f] isoquinolina útiles en el tratamiento del cáncer
DOP2019000081A (es) Modulador del regulador de conductancia de transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador
CR20210504A (es) Compuestos tricíclicos condensados útiles como agentes anticancerígenos
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
PE20200401A1 (es) Nuevos compuestos como inhibidores de autotaxina y composiciones farmaceuticas que comprenden a los mismos
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
EA201490807A1 (ru) Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1
AR056014A1 (es) Compuesto 3-aminocarbazol, composicion farmaceutica que lo contiene y procedimiento para la preparacion del mismo
CU20130116A7 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
CU20090196A7 (es) Metabolitos de derivados del (tio)-carbamoil-ciclohexano
CY1115058T1 (el) Παραγωγα 1,2,3- τριαζολης για χρηση ως αναστολεις στεατοϋλο-coa δεσατουρασης
MX2019006165A (es) Proceso para la preparacion de derivados del acido biliar de las sulfonilureas.
PH12014502586A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
AR078201A1 (es) Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos
ATE539750T1 (de) Trans-4-ä2-ä4-(2,3-dichlorophenyl)-piperazin-1- ylü-ethylü-n,n-dimethylcarbamoyl-cyclohexylamin zur behandlung von schizophrenie
MX2019006843A (es) Inhibidor de cdk4/6.
AR091687A1 (es) Formas solidas de inhibidores de fosfodiesterasa tipo 5
CY1124245T1 (el) Τρικυκλικα συγχωνευμενα παραγωγα πυριδινης-2-ενα και η χρηση τους ως αναστολεις brd4
EA201591957A1 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
CO2022004723A2 (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CL2020003015A1 (es) Conversión a escala preparativa de goniautoxinas en neosaxitoxina
CL2022002386A1 (es) Compuestos de amino pirimidina fusionados
AR058109A1 (es) Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie

Legal Events

Date Code Title Description
FC Application refused